v3.26.1
Segment Reporting
 12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company operates and manages its business as one operating segment, which primarily focuses on developing novel small molecule therapeutics to treat unmet medical needs in immune-mediated diseases. The Company’s Chief Executive Officer serves as the Company’s Chief Operating Decision Maker (CODM), who reviews consolidated financial information on a company-wide basis for purposes of allocating resources and assessing financial performance. The measure of segment assets is reported on the consolidated balance sheets as total assets. The following table represents selected financial information for our segment for the years ended December 31, 2025, 2024 and 2023, in thousands:
Year Ended December 31,
202520242023
Collaboration revenue$— $— $7,000 
Internal costs
Total salary / benefits21,800 21,228 30,105 
External costs by program
Zetomipzomib15,855 36,652 40,513 
KZR-261839 5,940 6,428 
Other protein secretion discovery programs33 289 5,604 
General and administrative9,523 10,888 13,663 
Other segment items (1)11,057 15,608 22,111 
Total operating expenses$59,107 $90,605 $118,424 
Loss from operations(59,107)(90,605)(111,424)
Interest income4,444 8,462 11,104 
Other expenses(1,370)(1,593)(1,550)
Consolidated segment net loss$(56,033)$(83,736)$(101,870)
(1) Other segment items include stock-based compensation expense, depreciation and amortization, loss on disposal of property and equipment, impairment loss of property and equipment, and in 2024 and 2023, impairment loss of right-of-use asset.